Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Covid-19

Molnupiravir reduces risk of hospitalization and death in patients with mild to moderate COVID-19

The antiviral’s developer, Merck & Co., says it will apply to the US FDA for Emergency Use Authorization

by Bethany Halford , Laura Howes , Megha Satyanarayana
October 1, 2021

Article:

This article has been sent to the following recipient: